Table 1 Demographic characteristics and OAB symptoms before treatment among studied patients in both groups
From: Overactive bladder symptoms recurrence after sudden versus gradual weaning of Solifenacin
Demographic characteristics | Treatment protocol | P value | |
|---|---|---|---|
Group I (sudden stopping) N = 30 | Group II (gradual weaning) N = 30 | ||
Age; (years) | |||
Mean ± SD | 48.10 ± 21.7 | 40.63 ± 14.04 | 0.119a |
95% CI1 for Mean | |||
Lower bound | 39.98 | 35.39 | |
Upper bound | 56.22 | 45.87 | |
Range (Max–Min) | 67.00 (77–22) | 46.00 (64–18) | |
Gender; n (%) | |||
Male; n = 21 | 10 (47.6) | 11 (52.4) | 0.500b |
Female; n = 39 | 20 (51.3) | 19 (48.7) | |
OABSS; (before treatment) | |||
Mean ± SD | 8.60 ± 1.8 | 8.13 ± 1.8 | 0.320a |
95% CI1 for Mean | |||
Lower bound | 7.93 | 7.48 | |
Upper bound | 9.26 | 8.79 | |
Range (Max–Min) | 5.00 (11–6) | 5.00 (11–6) | |